#USA #New York #Class Action #Investor Rights #Iovance Biotherapeutics

Overview

The Gross Law Firm has issued an urgent notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), highlighting the opportunity for those who experienced financial losses to join a class action lawsuit. Shareholders who bought shares of Iovance during the designated class period from May 9, 2024, to May 8, 2025, are particularly encouraged to take action. This class action aims to hold the company accountable for allegedly misleading disclosures that resulted in substantial losses for investors.

Background

During the class period, Iovance provided investors with optimistic statements regarding its growth potential and the demand for its treatments. However, the firm reportedly concealed critical information about its operational capabilities, which ultimately led to a significant decline in its stock price. On July 25, 2024, following the announcement of lower-than-expected financial results, the company reduced its revenue guidance for the fiscal year, which raised immediate concerns and resulted in a drastic drop in share prices. The stock plummeted by approximately 44.8%, closing at $1.75 per share on May 9, 2025, after being valued at $3.17 the previous day.

Class Action Details

As part of the class action, shareholders can assert their rights without needing to become lead plaintiffs. The firm assures that one need not be appointed to still participate in any potential recovery. Those interested in joining the class action are advised to promptly register by submitting their information through the specified link. The deadline to officially enroll and potentially be designated as a lead plaintiff is July 14, 2025.

Steps for Participants

To facilitate the registration process, participants who purchased IOVA shares during the specified timeframe will be enrolled in a monitoring system that provides case status updates throughout its duration. The Gross Law Firm stands out as a nationally recognized entity specializing in class actions, demonstrating a commitment to safeguarding investors from deceptive practices and ensuring accountability from corporations.

Why Choose Gross Law Firm?

The Gross Law Firm is dedicated to championing investor rights and has a track record of attaining favorable outcomes for clients who have suffered losses due to corporate misconduct. With their focus on responsible business practices and corporate ethics, they seek recovery for investors impacted by misleading information that inflated stock prices artificially.

Final Thoughts

Investors holding shares of Iovance Biotherapeutics must remain vigilant and proactive about their rights. The opportunity for recovery through this class action is crucial, particularly for those significantly impacted by recent events surrounding the company's misleading financial disclosures. With a team dedicated to defending the interests of shareholders, The Gross Law Firm provides an avenue for justice for misled investors.

For more information or to register as a participant, interested individuals can reach out to The Gross Law Firm using the contact information provided or visit their official website for further details.

Contact Information

• - Address: The Gross Law Firm, 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Investor protection should remain a priority, and shareholders of Iovance have the chance to pursue their claims through this class action, ensuring that those responsible for misleading information are held accountable.